Поиск патентов

Настройки

Глубина выборки

Укажите год

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Ключевые слова. Может быть несколько по одной на строку

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка

Автор

Ведите корректный номера.

Владелец

Ведите корректный номера.

Классы IPC

Ведите корректный номера.

Классы CPC

Ведите корректный номера.

Начиная с года

Укажите год

Заканчивая годом

Укажите год

Применить Всего найдено 9466. Отображено 100.

09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1

Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne R. Kindsvogel

Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее

Номер записи: 1

09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1

Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne A. Kindsvogel

Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее

Номер записи: 2

16-02-2012 дата публикации

Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Номер: US20120039916A1

Автор: Anne-Laure Flamar, Gérard ZURAWSKI, Jacques F. Banchereau

Принадлежит: BAYLOR RESEARCH INSTITUTE

Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.

Подробнее

Номер записи: 3

01-03-2012 дата публикации

Vaccine composition for prophylaxis and/or therapy of alzheimer's disease

Номер: US20120052086A1

Автор: Atsushi Takahashi, Hisakazu Hasegawa, Mikio Shoji, Takeshi Kawarabayashi, Teruhiko Terakawa, Yasushi Shimada

Принадлежит: Hokko Chemical Industry Co Ltd

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

Подробнее

Номер записи: 4

22-03-2012 дата публикации

Targeted multi-epitope dosage forms for induction of an immune response to antigens

Номер: US20120070493A1

Автор: Christopher Fraser, David H. Altreuter, Grayson B. Lipford

Принадлежит: Selecta Biosciences Inc

Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.

Подробнее

Номер записи: 5

29-03-2012 дата публикации

Novel malaria vaccine

Номер: US20120076816A1

Автор: Ken Ishii, Takahiro Tougan, Toshihiro Horii

Принадлежит: Osaka University NUC

The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X 1 -A-B-X 2 -Y-X 3 -(Y)n-X 4 -(Y)n-X 5 (1) (In the formula, X 1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X 2 represents the 73th to 177th amino acid residues; X 3 represents the 178th to 258th amino acid residues; X 4 represents the 259th to 289th amino acid residues; X 5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum ; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum ; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.)

Подробнее

Номер записи: 6

26-04-2012 дата публикации

Continuous Cell Programming Devices

Номер: US20120100182A1

Автор: David J. Mooney, Glenn Dranoff, Omar Ali

Принадлежит: Individual

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Подробнее

Номер записи: 7

03-05-2012 дата публикации

Synthetic Oligopeptides Designed From Mite Cysteine Proteases and Methods for the Production of

Номер: US20120107335A1

Автор: Catalina Sosa, Dary Luz Mendoza, Eduardo Egea, Elkin Navarro, Gloria Garavito, Johana Espejo, Luis Alejandro Barrera

Принадлежит: Fundacion Universidad del Norte Co, PONTIFICIA UNIVERSIDAD JAVERIANA

The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis , which can be used in the immunomodulation of individuals having immunocompetent systems and in the production of IgY polyclonal antibodies. The invention relates to a first method for obtaining a composition of IgY polyclonal antibodies that can be used as a diagnostic reagent having low cost and high reactivity in respect of intradomiciliary mites, and a second method for the detection of mite allergens, using the IgY antibody composition developed in the first method. The invention further relates to the composition of the IgY polyclonal antibodies.

Подробнее

Номер записи: 8

17-05-2012 дата публикации

Tat-Based Vaccine Compositions and Methods of Making and Using Same

Номер: US20120121636A1

Автор: David I. Cohen

Принадлежит: NANIRX Inc

A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based vaccine composition comprising immunostimulatory lentivirus Tat is provided.

Подробнее

Номер записи: 9

31-05-2012 дата публикации

Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines

Номер: US20120135038A1

Автор: Henry Daniell

Принадлежит: Individual

Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis , as well as Yersina pestis . The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.

Подробнее

Номер записи: 10

21-06-2012 дата публикации

Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Номер: US20120156282A1

Автор: Claus Aagaard, Jes Dietrich, Peter Andersen

Принадлежит: Statens Serum Institut SSI

A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes.

Подробнее

Номер записи: 11

12-07-2012 дата публикации

Lipid vesicle compositions and methods of use

Номер: US20120177724A1

Автор: Anjali Yadava, Darrell J. Irvine, Jaehyun MOON

Принадлежит: Massachusetts Institute of Technology

The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.

Подробнее

Номер записи: 12

26-07-2012 дата публикации

Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy

Номер: US20120190110A1

Автор: Angus G. Dalgleish, Brendan Meyer, Christine Galustian, George W. Muller, Justin B. Bartlett, Peter H. Schafer

Принадлежит: Individual

Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.

Подробнее

Номер записи: 13

23-08-2012 дата публикации

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2

Номер: US20120214737A1

Автор: Mark Marchionni

Принадлежит: Acorda Therapeutics Inc

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Подробнее

Номер записи: 14

27-09-2012 дата публикации

Use of tryptanthrin compounds for immune potentiation

Номер: US20120244182A1

Автор: Nicholas M. Valiante

Принадлежит: Novartis Vaccines and Diagnostics Inc

The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.

Подробнее

Номер записи: 15

11-10-2012 дата публикации

Method to identify a novel class of immunologic adjuvants

Номер: US20120258125A1

Автор: Carol O. Cowing, Christopher Cowing-Zitron

Принадлежит: LANCELL LLC

Methods of identifying an adjuvant capable of activating dendritic cells including measuring expression level genes in skin of an animal prior to exposure to a test compound, wherein the genes are known to be upregulated or downregulated in the skin of the animal in response to topical application of dibutyl phthalate (DBP) to skin of said animal; exposing skin of an animal of the same species to the test compound; measuring expression level of the genes in the skin of the animal after exposure to the test compound; and comparing expression level of the genes measured before and after exposure to the test compound, wherein an increase or decrease in expression level of the genes following exposure to the test compound indicates that the test compound is capable of activating dendritic cells. Also included are compositions that induce dendritic cell migration and modulate expression level of genes in skin cells.

Подробнее

Номер записи: 16

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells

Номер: US20120276155A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Подробнее

Номер записи: 17

01-11-2012 дата публикации

Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use

Номер: US20120276156A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Подробнее

Номер записи: 18

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Номер: US20120276158A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.

Подробнее

Номер записи: 19

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers

Номер: US20120276159A1

Автор: Christopher Fraser, Christopher J. ROY, Grayson B. Lipford, Roberto A. MALDONADO

Принадлежит: Selecta Biosciences Inc

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Подробнее

Номер записи: 20

08-11-2012 дата публикации

Methods and compositions for producing antigenic responses

Номер: US20120282284A1

Автор: Constance N. Wilson, Paul Borron

Принадлежит: Individual

The present inventions relates to methods of producing an antigenic response in which an antigen is contacted to an antigen-presenting cell, wherein the improvement comprises contacting the antigen-presenting cell with an A 1 adenosine receptor activating agent in an amount sufficient to increase the antigenic response of the antigen-presenting cell to the antigen. The present invention further provides methods, compositions, combination therapies, imaging techniques, and diagnostic kits that may improve the diagnosis, prognosis, and/or survival of cancer patients, pathogen-infected patients, and infectious or non-infectious immune-deficient patients.

Подробнее

Номер записи: 21

15-11-2012 дата публикации

Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants

Номер: US20120288525A1

Автор: Moriya Tsuji, Stephen L. Hoffman, Sumana CHAKRAVARTY

Принадлежит: Sanaria Inc

Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of α-galactosylceramide (α-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.

Подробнее

Номер записи: 22

29-11-2012 дата публикации

Antigen peptide and use thereof

Номер: US20120301495A1

Автор: Kenichiro Hasumi, Mikio Kuraya

Принадлежит: Individual

In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.

Подробнее

Номер записи: 23

06-12-2012 дата публикации

Dna vaccines and methods for the prevention of transplantation rejection

Номер: US20120308577A1

Автор: Alan P. Escher, Fengchun Li

Принадлежит: LOMA LINDA UNIVERSITY

Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipeint, as described herein, can induce a donor specific tolerogenic response.

Подробнее

Номер записи: 24

27-12-2012 дата публикации

Compositions and methods for vaccinating against hsv-2

Номер: US20120328656A1

Автор: Adrian Vilalta, David M. Koelle, Lichun Dong, Michal Margalith

Принадлежит: UNIVERSITY OF WASHINGTON, Vical Inc

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

Подробнее

Номер записи: 25

17-01-2013 дата публикации

Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses

Номер: US20130017188A1

Автор: Hulin Jin, Vijay K. Kuchroo

Принадлежит: Brigham and Womens Hospital Inc

The inventors have made the surprising discovery that SGK1, a serine/threonine kinase previously described as being involved in regulation of cellular sodium homeostasis, has a novel and unexpected function in the differentiation and function of a specific subset of CD4 T cells, the TH17 lineage. Described herein are methods and compositions for modulation of TH17 cell differentiation, proliferation, and/or function that rely upon modulating the activity or expression of SGK1. Such methods and compositions are useful in the treatment of disorders including autoimmune diseases, chronic inflammatory conditions, infectious diseases, and cancer.

Подробнее

Номер записи: 26

14-02-2013 дата публикации

Immunogenic pote peptides and methods of use

Номер: US20130039936A1

Автор: Ira H. Pastan, Jay A. Berzofsky, Masaki Terabe, Yi-Hsiang Huang

Принадлежит: US Department of Health and Human Services

POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.

Подробнее

Номер записи: 27

14-02-2013 дата публикации

Compositions and Methods for Self-Adjuvanting Vaccines against Microbes and Tumors

Номер: US20130039942A1

Автор: Geoffrey William Stone, Richard Syd Kornbluth

Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immuno stimulator intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.

Подробнее

Номер записи: 28

07-03-2013 дата публикации

Kexin-Derived Vaccines to Prevent or Treat Fungal Infections

Номер: US20130058891A1

Автор: Jay K. Kolls, Mingquan Zheng

Принадлежит: Individual

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

Подробнее

Номер записи: 29

04-04-2013 дата публикации

Vaccine and methods to reduce campylobacter infection

Номер: US20130084304A1

Автор: Billy Hargis, Neil R. Pumford, Sherryll Layton, Young Min Kwon

Принадлежит: University of Arkansas

Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

Подробнее

Номер записи: 30

11-04-2013 дата публикации

Oral vaccine compromising an antigen and a toll-like receptor agonist

Номер: US20130089570A1

Автор: Corey Patrick MALLETT, Daniel Larocque, Martin Plante, Nadia Ouaked

Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition.

Подробнее

Номер записи: 31

16-05-2013 дата публикации

Hmgb1-derived peptides enhance immune response to antigens

Номер: US20130122031A1

Автор: Davorka Messmer, Rebecca Saenz

Принадлежит: Individual

The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. The invention also provides an immunostimulatory peptide containing the amino acid sequence DPNAPKRPPSAFFLX 1 X 2 X 3 X 4 or derivatives thereof. In one embodiment, when X1 is alanine (A), glycine (G), or valine (V) then X2 is C, X3 is S and X4 is E; wherein when X2 is alanine (A), glycine (G), or valine (V) then X1 is F, X3 is S and X4 is E; wherein when X3 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X4 is E; or wherein when X4 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X3 is S.

Подробнее

Номер записи: 32

30-05-2013 дата публикации

Immunostimulating Polyphosphazene Compounds

Номер: US20130136758A1

Автор: Alexander Andrianov, Alexander Marin

Принадлежит: Individual

Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed.

Подробнее

Номер записи: 33

06-06-2013 дата публикации

Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation

Номер: US20130142818A1

Автор: Karl-Josef Kallen, Patrick Baumhof, Söhnke Voss, Thomas Kramps

Принадлежит: CureVac AG

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned above. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and/or the inventive pharmaceutical composition, adjuvant or vaccine in one or more parts of the kit.

Подробнее

Номер записи: 34

13-06-2013 дата публикации

Vaccine composition based on sticholysin encapsulated into liposomes

Номер: US20130149376A1

Автор: Aisel Valle Garay, Carlos Manuel Alvarez Valcarcel, Circe Mesa Pardillo, Isabel Fabiola Pazos Santos, Liem Canet Santos, Luis Enrique Fernandez Molina, Maria Del Carmen Luzardo Lorenzo, Maria Eliana Lanio Ruiz, Maria Eugenia Alonso Biosca, Mayra Tejuca Martinez, Rady Judith Laboroe Quintana, Yoelys Cruz Leal

Принадлежит: Centro de Immunologia Molecular

The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine:cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The disclosed compositions allow modulation of CTL-specific immune response against one or several antigens co-encapsulated into toxin-containing liposomes. The vaccinal vehicle of the present invention shows advantages over others disclosed by the previous art due to the robustness and functionality of the induced immune response as well as its immunomodulating properties.

Подробнее

Номер записи: 35

11-07-2013 дата публикации

Lipid Based Adjuvants for DNA Plasmids

Номер: US20130177591A1

Автор: Alexis Parisot, Caroline Edlund Toulemonde

Принадлежит: Merial LLC

The present invention provides for a novel vaccine formulation comprising plasmid DNA and a lipid adjuvant. The invention also provides for prime-boost vaccination methods wherein two sequential administration of the same plasmid-based DNA vaccine provide companion animals with protection against rabies for at least one year.

Подробнее

Номер записи: 36

11-07-2013 дата публикации

Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes

Номер: US20130178613A1

Автор: Charles J. Link, Firoz Jaipuri, Gabriela Rossi, Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young

Принадлежит: NewLink Genetics Corp

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Подробнее

Номер записи: 37

18-07-2013 дата публикации

Synthetic immunogen useful for generating long lasting immunity and protection against pathogens

Номер: US20130183377A1

Автор: David Jackson, Javed Naim Agrewala, Uthaman Gowthaman, Weiguang Zeng

Принадлежит: Council of Scientific and Industrial Research CSIR, University of Melbourne

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X 1 =a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X 2 =a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

Подробнее

Номер записи: 38

12-09-2013 дата публикации

Fgf modulation of in vivo antibody production and humoral immunity

Номер: US20130236483A1

Автор: Andrew B. Bush

Принадлежит: Individual

The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.

Подробнее

Номер записи: 39

19-09-2013 дата публикации

Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection

Номер: US20130243805A1

Автор: Claire Coeshott, David Apelian, Thomas H. King, Zhimin Guo

Принадлежит: Globeimmune Inc

Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.

Подробнее

Номер записи: 40

10-10-2013 дата публикации

Phospholipid drug analogs

Номер: US20130267481A1

Автор: Alcide Barberis, Emanuela Mura, Franco Pattarino, Roberto Maj

Принадлежит: Telormedix SA

Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X 2 is a bond or linker, X 3 is bond or —PO 4 —, and X 1 , R 1 , R 2 , R 3 , and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.

Подробнее

Номер записи: 41

24-10-2013 дата публикации

Dna vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused m2 protein

Номер: US20130280296A1

Автор: Shih-Chang Lin, Suh-Chin Wu

Принадлежит: National Tsing Hua University NTHU

A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided

Подробнее

Номер записи: 42

07-11-2013 дата публикации

Recombinant virus expressing foreign dna encoding feline cd80, feline cd86, feline cd28, or feline ctla-4 and uses thereof

Номер: US20130295133A1

Автор: Barbara J. Winslow, Ellen W. Collisson, In-Soo Choi, Mark D. Cochran, Stephen M. Hash

Принадлежит: Intervet Inc, TEXAS A&M UNIVERSITY SYSTEM

The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropriate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune response in a feline.

Подробнее

Номер записи: 43

05-12-2013 дата публикации

Mammalian cell surface antigens; related reagents

Номер: US20130324483A1

Автор: Albert Zlotnik, Daniel M. Gorman, Troy D. Randall

Принадлежит: Merck Sharp and Dohme LLC

Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

Подробнее

Номер записи: 44

19-12-2013 дата публикации

Controlled activation of complement components for use as endogenous adjuvant

Номер: US20130337045A1

Автор: Carsten Schmidt-Weber, Edzard Spillner, Markus Ollert, Reinhard Bredehorst, Thomas Grunwald

Принадлежит: Helmholtz Zentrum Munchen Forschungszentrum fur Gesundheit und Umwelt GmbH, Klinikum Rechts der Isar der Technischen Universitaet Muenchen, PLS-DESIGN GMBH

The invention relates to a pharmaceutical composition made of one or more preparation and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and at least one antigen für vaccination.

Подробнее

Номер записи: 45

26-12-2013 дата публикации

Immunogenic Compositions

Номер: US20130344109A1

Автор: Ausra Mancevski, Francois Dalencon, Jean Haensler, Jin Su, Nathalie Reveneau, Scott Gallichan

Принадлежит: Sanofi Pasteur Ltd, Sanofi Pasteur SA

The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis ) in a subject, by administering to the subject a composition of the invention.

Подробнее

Номер записи: 46

06-03-2014 дата публикации

Compositions and Methods for Cancer Immunotherapy

Номер: US20140065100A1

Автор: Daniel P. Rossignol, Lynn D. Hawkins, Sally T. Ishizaka, Scott Fields

Принадлежит: Eisai R&D Management Co Ltd

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

Подробнее

Номер записи: 47

06-01-2022 дата публикации

ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT

Номер: US20220001010A1

Автор: LIWSKI Robert, MacDonald Lisa Diana, Mansour Marc, Weir Genevieve Mary

Принадлежит: Immunovaccine Technologies Inc.

The present disclosure provides adjuvanting systems comprising: (a) a polyI:C polynucleotide adjuvant; (b) a lipid-based adjuvant;(c) an amphipathic compound; and (d) a hydrophobic carrier. Also provided are vaccine compositions that are water-free or substantially free of water, which comprise the same components together with one or more antigens. The disclosure also provides uses for such compositions in inducing an antibody (humoral) and/or cell-mediated immune response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by an antibody and/or cell-mediated immune response. 129-. (canceled)30. An adjuvanting system comprising:(a) a polyI:C polynucleotide adjuvant in an amount of less than about 100 micrograms per unit dose for humans;(b) a lipid-based adjuvant in an amount of less than about 100 micrograms per unit dose for humans, wherein the lipid-based adjuvant comprises palmitic acid as the lipid component;(c) an amphipathic compound; and(d) a hydrophobic carrier, wherein the hydrophobic carrier is an oil or a mixture of oils selected from a vegetable oil, nut oil, and mineral oil, or the hydrophobic carrier is a mannide oleate in mineral oil solution.31. A composition comprising the adjuvanting system of and an antigen claim 30 , wherein the composition is water-free or substantially free of water.32. The composition of claim 31 , comprising less than about 50 micrograms of the polyI:C polynucleotide adjuvant and less than about 50 micrograms of the lipid-based adjuvant per unit dose for humans.33. The composition of claim 31 , comprising less than about 10 micrograms of the polyI:C polynucleotide adjuvant and less than about 10 micrograms of the lipid-based adjuvant per unit dose for humans.34. The composition of claim 31 , comprising less than about 5 micrograms of the polyI:C polynucleotide adjuvant and less than about 5 micrograms of the lipid-based adjuvant per unit dose for humans.35. The composition of claim 31 , ...

Подробнее

Номер записи: 48

04-01-2018 дата публикации

MACROPHAGES EAT CANCER CELLS USING THEIR OWN CALRETICULIN AS A GUIDE

Номер: US20180000865A1

Автор: FENG Mingye, Volkmer Jens-Peter, Weissman Irving L.

Принадлежит:

Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD47 blockade. 1. A method of increasing phagocytosis of cancer cells , the method comprising:contacting a population of phagocytic cells with a TLR agonist in a dose effective to increase expression of calreticulin on the phagocytic cell surface; and with an effective dose of a CD47 blocking agent;wherein programmed cell removal of cancer cells by the phagocytic cells is increased.2. The method of claim 1 , wherein the contacting is performed in vivo.3. The method of claim 1 , wherein the contacting is performed in vitro.4. The method of claim 1 , wherein the phagocytic cells are macrophages.5. The method of claim 1 , wherein the TLR agonist is imiquimod.6. The method of claim 1 , wherein the TLR agonist is poly I:C.7. The method of claim 1 , wherein the CD47 blocking agent is an antibody.8. The method of claim 7 , wherein the antibody specifically binds to CD47.9. The method of claim 3 , wherein the phagocytic cells are introduced into a subject following the contacting with a TLR agonist and a CD47 blocking agent.10. The method of claim 9 , wherein expression of calreticulin on the phagocytic cell surface is measured prior to the introducing step.11. A method of protecting blood cells from phagocytosis claim 9 , the method comprising:contacting said cells with a BTK inhibitory agent.12. The method of claim 11 , wherein blood cells in a subject are contacted with a BTK inhibitory agent in vivo.13. The method of claim 12 , ...

Подробнее

Номер записи: 49

07-01-2021 дата публикации

MEDICINE

Номер: US20210000916A1

Автор: DOI Shun, MIYAKAWA Tomoya, Tamada Koji

Принадлежит: CYTLIMIC INC.

The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof. 1. A medicine comprisingPoly I:C or a salt thereof anda fusion protein of LAG-3 protein and IgG.2. The medicine according to claim 1 , for combined administration ofPoly I:C or a salt thereof anda fusion protein of LAG-3 protein and IgG.3. The medicine according to claim 1 , further comprising at least one type of cancer-antigen derived peptide.4. The medicine according to claim 3 , for combined administration ofPoly I:C or a salt thereof,a fusion protein of LAG-3 protein and IgG, andat least one type of cancer-antigen derived peptide.5. The medicine according to claim 3 , comprising two or more cancer-antigen derived peptides. This application is a Divisional of U.S. application Ser. No. 15/564,604, which is the U.S. National Stage application of PCT/JP2016/061463, filed Apr. 7, 2016, which claims priority from Japanese application nos. JP 2015-078684, filed Apr. 7, 2105, JP 2015-198066, filed Oct. 5, 2015, and JP 2016-032046, filed Feb. 23, 2016.The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-WEB and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 14, 2020, is named sequence.txt and is 669 bytes.The present invention relates to a medicine or the like containing a Toll-like receptor agonist and LAG-3 protein, a variant or derivative thereof.Recently, cancer immunotherapies targeting cancer antigens expressed specifically in cancer cells have been developed. Of them, a “cancer vaccine therapy” is a method of inducing regression of cancer by administering a cancer antigen directly to patients to induce an immune response specific to a cancer antigen in the patient's body. As the cancer antigen to be administered to a patient, e.g., a cancer-antigen protein itself, a cancer-antigen derived peptide, a nucleic acid encoding them, a dendritic cell ...

Подробнее

Номер записи: 50

07-01-2021 дата публикации

Polymer adjuvant

Номер: US20210000934A1

Автор: Geoffrey Lynn, Kerry Fisher, Leonard Seymour, Richard LAGA, Robert Seder

Принадлежит: Oxford University Innovation Ltd, US Department of Health and Human Services

The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.

Подробнее

Номер записи: 51

07-01-2021 дата публикации

VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES

Номер: US20210000945A1

Автор: FROMM George, Schreiber Taylor

Принадлежит:

Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided. 1. An expression vector comprising a first nucleotide sequence that encodes a secretable vaccine protein , and a second nucleotide sequence that encodes a T cell costimulatory fusion protein comprising TL1A-Ig , wherein the TL1A-Ig protein comprises an amino acid sequence having at least 97% to SEQ ID NO: 9 and enhances activation of antigen-specific T cells when administered to a subject.2. The expression vector of claim 1 , wherein the vector is a mammalian expression vector.3. The expression vector of claim 1 , wherein the secretable vaccine protein is a gp96-Ig fusion protein that lacks the gp96 KDEL (SEQ ID NO:3) sequence.4. The expression vector of claim 3 , wherein the Ig tag in the gp96-Ig fusion protein comprises the Fc region of human IgG1 claim 3 , IgG2 claim 3 , IgG3 claim 3 , or IgG4.512-. (canceled)13. The expression vector of claim 1 , wherein the expression vector comprises DNA.14. The expression vector of claim 1 , wherein the expression vector comprises RNA.1526-. (canceled)27. The expression vector of claim 1 , wherein the expression vector is incorporated into a virus or virus-like particle.28. The expression vector of claim 1 , wherein the expression vector is incorporated into a human tumor cell.29. The expression vector of claim 28 , wherein the human tumor cell is a cell from an established non-small cell lung carcinoma (NSCLC) claim 28 , bladder cancer claim 28 , melanoma claim 28 , ovarian cancer claim 28 , renal cell carcinoma claim 28 , prostate carcinoma claim 28 , sarcoma claim 28 , breast carcinoma claim 28 , squamous cell carcinoma claim 28 , head and neck carcinoma claim 28 , hepatocellular carcinoma ...

Подробнее

Номер записи: 52

07-01-2021 дата публикации

PD-1 Peptide Inhibitors

Номер: US20210000948A1

Автор: Ayala Ramses, Gutierrez Gabriel M., Kotraiah Vinayaka, Pannucci James

Принадлежит:

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis. 1. A method of inhibiting progression of a hyperproliferative disorder , to treat an infectious disease , or to treat sepsis , comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising: (i) a peptide consisting of the amino acid sequence SEQ ID NO:1;', '(ii) a peptide consisting of the amino acid sequence SEQ ID NO:2;', '(iii) a peptide consisting of the amino acid sequence SEQ ID NO:3; and', '(iv) a peptide consisting of the amino acid sequence SEQ ID NO:4; and, '(a) up to four peptides selected from the group consisting of(b) a pharmaceutically acceptable vehicle.2. The method of claim 1 , wherein the composition is administered to inhibit progression of a hyperproliferative disorder.3. The method of claim 2 , wherein the hyperproliferative disorder is a cancer.4. The method of claim 3 , wherein the cancer is a melanoma.5. The method of claim 3 , further comprising administering a cancer vaccine to the patient.6. The method of claim 2 , further comprising administering a chimeric antigen receptor (CAR) T cell therapy to the patient.7. The method of claim 1 , wherein the composition is administered to treat an infectious disease.8. The method of claim 7 , wherein the infectious disease is malaria.9. The method of claim 7 , wherein the infectious disease is hepatitis B.10. The method of claim 7 , wherein the composition is administered as a vaccine adjuvant to a vaccine against the infectious disease.11. The method of claim 1 , wherein the composition is administered to treat sepsis.12. The ...

Подробнее

Номер записи: 53

03-01-2019 дата публикации

VACCINE COMPOSITIONS

Номер: US20190000961A1

Автор: Drew Jeffrey

Принадлежит:

The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: Rrepresents Calkyl; Rrepresents hydrogen or Calkyl; and Rrepresents Calkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient. 2. Use according to claim 1 , in which the compound of formula (I) is dimethylglycine or trimethylglycine.3. Use according to claim 2 , in which the compound of formula (I) is dimethylglycine.4. Use according to any one of to claim 2 , in which the aqueous composition further comprises one or more sugars.5. Use according to claim 4 , in which the one or more sugars are sucrose and raffinose.6. Use according to any one of the preceding claims claim 4 , in which the aqueous composition further comprises an adjuvant.7. Use according to claim 6 , in which the adjuvant is an aluminium salt adjuvant8. Use according to any one of the preceding claim 6 , in which the immunogenicity of the influenza antigen is increased during the (a) freezing claim 6 , (b) heat-treating claim 6 , and/or (c) freeze-drying of the aqueous composition.9. A method for increasing the immunogenicity of an influenza antigen claim 6 , said method comprising (a) freezing claim 6 , (b) heat-treating claim 6 , and/or (c) freeze-drying an aqueous composition comprising the influenza antigen claim 6 , an excipient as defined in any one of to claim 6 , optionally one or more sugars as defined in or and optionally an adjuvant as defined in or .10. A vaccine composition obtainable by the method defined in .11. A vaccine composition as defined in claim 10 , for use in the prevention of an influenza infection in a human or animal patient.12. A vaccine composition for use according to claim 11 , wherein the patient is (a) a child claim 11 , an elderly patient and/or a ...

Подробнее

Номер записи: 54

03-01-2019 дата публикации

Vector co-expressing vaccine and costimulatory molecules

Номер: US20190000967A1

Автор: George FROMM, Taylor Schreiber

Принадлежит: Heat Biologics Inc

Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.

Подробнее

Номер записи: 55

03-01-2019 дата публикации

ADJUVANT COMPOSITION CONTAINING AT LEAST ONE INFLUENZA VIRUS NEUTRALIZING AND BINDING MOLECULE AND VACCINE COMPOSITION CONTAINING SAME

Номер: US20190000968A1

Автор: Ahn Jung Sun, Chang Shin Jae, CHOI Jung Ah, Keum Sun Ju, Kim Pan Kyeom, Lee Soo Young, Lim Byung Pil, Park Eun Bee, Park Sang Tae, SONG Man Ki

Принадлежит: CELLTRION INC.

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses. 19-. (canceled)10. A method of enhancing an immune response to a target antigen , comprising administering a vaccine composition comprising at least one binding molecule for neutralizing an influenza virus and a target antigen to a host.11. A method of preparing an immunological product , comprising:(a) immunizing a host by administering a vaccine composition comprising at least one binding molecule for neutralizing an influenza virus and a target antigen to the host; and(b) obtaining an immunological product from the immunized host, wherein the immunological product is a T cell, a B cell or an antibody against a target antigen comprised in the vaccine composition.12. A method of enhancing an immune response to an influenza A virus in a Subject which comprises administering to the subject a vaccine composition comprising a complex of the influenza A virus and an antibody directed to the influenza A virus.13. The method of claim 12 , wherein the antibody is specifically bound to the influenza A virus and the complex binds to an Fc receptor of immune cells.14. The method of claim 12 , wherein the ratio by weight of the influenza A virus to the antibody directed to the influenza A virus in the complex is between 1:0.02 and 1:200.15. The method of claim 12 , wherein the antibody directed to the influenza A virus bind to at least one epitope selected from the group consisting of i) an epitope comprising an amino acid residue selected from the group consisting of the amino acids at positions 18 claim ...

Подробнее

Номер записи: 56

02-01-2020 дата публикации

Novel Compounds

Номер: US20200002370A1

Автор: ADAMS Jerry, LIAN Yiqian

Принадлежит:

A compound of Formula (I) 2. The method of wherein the cancer is melanoma.3. The method of wherein the cancer is head and neck cancer.4. The method of wherein the compound is administered by intratumoral injection.5. The method of wherein the compound is administered by peritumoral injection.6. The method of wherein the cancer is squamous cell carcinomas.7. The method of wherein the cancer is breast cancer.8. The method of wherein the compound is administered by intratumoral injection.9. The method of wherein the compound is administered by peritumoral injection.10. The method of wherein the cancer is hepatocellular cancer.11. The method of wherein the cancer is colon cancer.12. The method of wherein the cancer is esophageal cancer.13. The method of wherein the cancer is rectal cancer.14. The method of wherein the cancer is lung cancer.15. The method of wherein the compound is administered by intratumoral injection.16. The method of wherein the compound is administered by peritumoral injection.17. The method of wherein the cancer is renal cell cancer.18. The method of wherein claim 1 , the cancer is selected from: melanoma claim 1 , squamous cell carcinomas claim 1 , hepatocellular cancer claim 1 , colon cancer claim 1 , esophageal cancer claim 1 , rectal cancer claim 1 , and renal cell cancer claim 1 , and the compound is administered by intratumoral injection.19. The method of claim 1 , the wherein claim 1 , the cancer is selected from: melanoma claim 1 , squamous cell carcinomas claim 1 , hepatocellular cancer claim 1 , colon cancer claim 1 , esophageal cancer claim 1 , rectal cancer claim 1 , and renal cell cancer claim 1 , and the compound is administered by peritumoral injection.20. The method of wherein the cancer is selected from: brain (gliomas) claim 1 , glioblastomas claim 1 , astrocytomas claim 1 , glioblastoma multiforme claim 1 , Bannayan-Zonana syndrome claim 1 , Cowden disease claim 1 , Lhermitte-Duclos disease claim 1 , Wilm's tumor claim 1 , Ewing' ...

Подробнее

Номер записи: 57

03-01-2019 дата публикации

NOVEL PEPTIDE AND USE THEREOF

Номер: US20190002505A1

Автор: Koriyama Hiroshi, MORISHITA Ryuichi, Nakagami Hironori, TENMA Akiko

Принадлежит: OSAKA UNIVERSITY

The invention provides a peptide and an immunostimulant or hair grower containing the peptide as an active ingredient, as well as a method for hair growth or regrowth promotion by administering an effective amount of the peptide to a mammal. The peptide has 23 or less amino acids and includes the amino acid sequence LHRLKRLRKRL (SEQ ID NO: 1), preferably the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9). 1. A method for hair growth or regrowth promotion , comprising administering an effective amount of a peptide of 23 or less amino acids comprising the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9) to a mammal.2. The method of claim 1 , wherein the peptide comprises the amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 2) or an amino acid sequence having 90% or more identity with the amino acid sequence ELKLIFLHRLKRLRKRLKRK.3. The method of claim 2 , wherein the peptide is amidated at the C-terminus.4. The method of claim 3 , wherein the peptide is acetylated at the N-terminus5. The method of claim 2 , wherein the peptide is acetylated at the N-terminus.6. The method of claim 1 , wherein the peptide is amidated at the C-terminus.7. The method of claim 6 , wherein the peptide is acetylated at the N-terminus.8. The method of claim 1 , wherein the peptide is acetylated at the N-terminus. This patent application is a divisional of copending U.S. patent application Ser. No. 15/514,310, filed on Mar. 24, 2017, which is the U.S. national phase of International Patent Application No. PCT/JP2015/077139, filed Sep. 25, 2015, which claims the benefit of Japanese Patent Application No. 2014-197386, filed on Sep. 26, 2014, which are incorporated by reference in their entireties herein.Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 3,902 bytes ASCII (Text) file named “740543SequenceListing.txt,” created Sep. 14, 2018.The present invention relates to a ...

Подробнее

Номер записи: 58

01-01-2015 дата публикации

Compositions and methods for generating an immune response

Номер: US20150004132A1

Автор: Bernard Moss, Dennis Ellenberger, Harriet Robinson, James Smith, Ram Amara, Salvatore T. Butera

Принадлежит: Centers of Disease Control and Prevention CDC, EMORY UNIVERSITY, US Department of Health and Human Services

We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).

Подробнее

Номер записи: 59

20-01-2022 дата публикации

METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)

Номер: US20220016239A1

Автор: Kanako Shimizu, Keisuke Ohsumi, Masayuki KANKI, Shinichiro Fujii, Taku Yoshida

Принадлежит: Astellas Pharma Inc, RIKEN Institute of Physical and Chemical Research

[Problem to be Solved]Provided is an effective and safe method for treating or preventing a cancer using aAVC.[Solution]The present invention finds suitable ranges of the dose of α-GalCer loaded on aAVC cell surface, and the amount of α-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Подробнее

Номер записи: 60

12-01-2017 дата публикации

Multivalent Stable Vaccine Composition and Methods of Making Same

Номер: US20170007682A1

Автор: Brey Robert, Schaber Christopher

Принадлежит:

Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual. 1. An immunogenic composition comprising a first antigen comprising a ribosome inactivating protein and a second antigen comprising a toxin derived from bacterial spores , wherein the immunogenic composition is formulated to elicit protective immunity to each of the first and second antigenic components without causing immune interference between the first and the second antigens after administration to an individual.2. The composition of claim 1 , wherein the composition yields a measurable increase in neutralizing antibodies to the first antigen comprising the ribosome inactivating protein.3. The composition of claim 1 , wherein the composition is capable of yielding a measurable increase in neutralizing antibodies to the second antigen comprising a toxin derived from bacterial spores.4. The composition of claim 1 , wherein the composition is capable of yielding a measurable increase in neutralizing antibodies to both the first and the second antigen.5. The composition of claim 1 , wherein the composition elicits a measurable increase in neutralizing antibodies to the first antigen at least 200 days post-administration.6. The composition of claim 1 , wherein the composition ...

Подробнее

Номер записи: 61

12-01-2017 дата публикации

METHODS AND COMPOSITIONS FOR NANOEMULSION VACCINE FORMULATIONS

Номер: US20170007689A1

Автор: Ciotti Susan

Принадлежит: NanoBio Corporation

The present disclosure relates to nanoemulsion vaccine compositions and methods of making and using the same. The disclosed compositions and methods provide a means of treating, preventing, or protecting an individual from anthrax exposure or poisoning. 1. A vaccine composition comprising a recombinant protective antigen (rPA) of anthrax , a nanoemulsion , and a stabilizing system , wherein the stabilizing system comprises:(a) at least one buffer which is TRIS or PBS;(b) at least one of (i) at least one salt; (ii) at least one sugar such as trehalose or sucrose; (iii) at least one amino acid; or (iv) at least one antioxidant.2. The vaccine composition of claim 1 , wherein the vaccine composition consists of rPA claim 1 , the nanoemulsion claim 1 , and the stabilizing system.3. The vaccine composition of claim 1 , wherein the concentration of rPA is about 100 μg/ml.4. The vaccine composition of claim 1 , wherein the concentration of rPA is about 500 μg/ml.5. The vaccine composition of claim 1 , wherein the nanoemulsion is W5EC nanoemulsion adjuvant.6. The vaccine composition of claim 5 , wherein the W5EC nanoemulsion adjuvant is in a concentration of about 20%.7. The vaccine composition of claim 1 , wherein the TRIS buffer is in a concentration of 5-100 mM.8. The vaccine composition of claim 7 , wherein the TRIS buffer is in a concentration of about 10 mM.9. The vaccine composition of claim 7 , wherein the TRIS buffer is in a concentration of about 80 mM.10. The vaccine composition of claim 1 , wherein the salt is sodium chloride.11. The vaccine composition of claim 10 , wherein the sodium chloride is in a concentration of about 50-about 150 mM.12. The composition of claim 1 , wherein the salt is calcium chloride.13. The composition of claim 12 , wherein the calcium chloride is in a concentration of about 50-about 150 mM.14. The composition of claim 1 , wherein the sugar is trehalose.15. The composition of claim 14 , wherein the trehalose is in a concentration of ...

Подробнее

Номер записи: 62

14-01-2016 дата публикации

METHOD FOR TREATING A beta-AMYLOIDOSIS

Номер: US20160008443A1

Автор: MANDLER Markus, Mattner Frank, Schmidt Walter, Zauner Wolfgang

Принадлежит: Affiris AG

The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating β-amyloidoses including Alzheimer's disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and protein D (protein D). 1. A method for treating a β-amyloidosis , a disease associated with β-amyloid formation and/or aggregation , comprising administering to a subject in need thereof at least one mimotope of an epitope of alpha-synuclein ,{'i': 'Haemophilus influenzae', 'wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and protein D (protein D).'}2. The method according to claim 1 ,wherein the non-toxic diphtheria toxin mutant is selected from the group consisting of CRM 197, CRM 176, CRM 228, CRM 45, CRM 9, CRM 102, CRM 103 and CRM 107, in particular CRM 197.3. The method according to claim 1 ,wherein the at least one mimotope is formulated with at least one adjuvant.4. The method according to claim 1 ,wherein at least one adjuvant stimulates the innate immune system.5. The method according to claim 1 ,wherein at least one adjuvant that stimulates the innate immune system comprises or consists of a Toll-like receptor (TLR) agonist.6. The method according to claim 5 ,wherein the TLR agonist is selected from the group consisting of monophosphoryl lipid A (MPL), 3-de-O-acylated monophosphoryl lipid A (3D-MPL), poly I:C, GLA, flagellin, R848, imiquimod and CpG.7. The method according to claim 1 ,wherein the at least one adjuvant comprises or consists of a saponin, preferably QS21, a water in oil emulsion ...

Подробнее

Номер записи: 63

14-01-2016 дата публикации

XBP1, CD138, AND CS1 PEPTIDES

Номер: US20160008444A1

Автор: Anderson Kenneth C., Bae Jooeun, Munshi Nikhil C.

Принадлежит:

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells. 1128-. (canceled)129. A composition comprising:(a) a first XBP-1 peptide comprising the amino acid sequence of SEQ ID NO:6, up to 10 amino acids immediately N-terminal of SEQ ID NO: 6, and up to 10 amino acids immediately C-terminal of SEQ ID NO: 6,(b) a second XBP-1 peptide comprising the amino acid sequence of SEQ ID NO:10, up to 10 amino acids immediately N-terminal of SEQ ID NO: 10, and up to 10 amino acids immediately C-terminal of SEQ ID NO: 10, and(c) a CD138 peptide comprising the amino acid sequence of SEQ ID NO:12, up to 10 amino acids immediately N-terminal of SEQ ID NO: 12, and up to 10 amino acids immediately C-terminal of SEQ ID NO: 12.130. The composition of claim 129 , wherein:(a) the first XBP-1 peptide comprises up to 5 amino acids immediately N-terminal of SEQ ID NO: 6, and up to 5 amino acids immediately C-terminal of SEQ ID NO: 6;(b) the second XBP-1 peptide comprises up to 5 amino acids immediately N-terminal of SEQ ID NO: 10, and up to 5 amino acids immediately C-terminal of SEQ ID NO: 10; and(c) the CD138 peptide comprises up to 5 amino acids immediately N-terminal of SEQ ID NO: 12, and up to 5 amino acids immediately C-terminal of SEQ ID NO: 12.131. The composition of claim 129 , wherein:(a) the first XBP-1 peptide consists of the amino acid sequence of SEQ ID NO: 6;(b) the second XBP-1 peptide consists of the amino acid sequence of SEQ ID NO: 10; and(c) the CD138 peptide consists of the amino acid sequence of ...

Подробнее

Номер записи: 64

14-01-2016 дата публикации

COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS

Номер: US20160008447A1

Автор: Hacohen Nir, WU Catherine Ju-Ying

Принадлежит:

The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses. 1. A method of identifying a neoantigen comprising:a. identifying a tumor specific mutation in an expressed gene of a subject having cancer, 'i. identifying a mutant peptide having the mutation identified in step (a), wherein said mutant peptide binds to a class I HLA protein with a greater affinity than a wild-type peptide; and has an IC50 less than 500 nm;', 'b. wherein when said mutation identified in step (a) is a point mutation 'i. identifying a mutant polypeptide encoded by the mutation identified in step (a), wherein said mutant polypeptide binds to a class I HLA protein.', 'c. wherein when said mutation identified in step (a) is a splice-site, frameshift, read-through or gene-fusion mutation2. The method of claim 1 , wherein the mutant peptide is about 8-10 amino acids in length.3. The method of claim 1 , wherein the mutant peptide is greater than 10 amino acids in length.4. The method of claim 3 , wherein the mutant peptide is greater than 15 amino acids in length.5. The method of claim 4 , wherein the mutant peptides is greater than 20 amino acids in length.6. The method of claim 5 , wherein the mutant peptides is greater than 30 amino acids in length.7. The method of claim 1 , wherein the mutant peptides is about 8 to 50 amino acids in length.8. The method of claim 1 , wherein the mutant peptides is about 24-40 amino acids in length.9. The method of claim 1 , wherein tumor specific mutations are identified by nucleic acid sequencing.10. The method of claim 1 , further comprising selecting a peptide identified in step (b) or the polypeptide of step (c) that activates ...

Подробнее

Номер записи: 65

11-01-2018 дата публикации

CHIKAGUNYA VIRUS RNA VACCINES

Номер: US20180008694A1

Автор: Ciaramella Giuseppe, Himansu Sunny, Huang Eric Yi-Chun, Zaks Tal

Принадлежит: ModernaTX, Inc.

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease. 1185-. (canceled)186. A Chikungunya virus (CHIKV) vaccine comprising at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one antigenic CHIKV polyprotein comprising C protein , E1 protein , E2 protein and E3 protein formulated in a lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid , 5-25% non-cationic lipid , 25-55% sterol , and 0.5-15% PEG-modified lipid , in an effective amount to induce an immune response in the subject.187. The CHIKV vaccine of claim 186 , wherein the at least one antigenic CHIKV polyprotein further comprises 6K protein.188. The CHIKV vaccine of claim 186 , wherein the at least one RNA polynucleotide further encodes at least one 5′ terminal cap claim 186 , 7mG(5′)ppp(5′)NlmpNp.189. The CHIKV vaccine of claim 186 , wherein at least 80% of the uracil in the open reading frame have a chemical modification selected from N1-methyl-pseudouridine or N1-ethyl-pseudouridine.190. The CHIKV vaccine of claim 189 , wherein the chemical modification is in the 5-position of the uracil.191. The CHIKV vaccine of claim 186 , wherein the efficacy of the vaccine is at least 60% claim 186 , relative to unvaccinated subjects claim 186 , following a single dose of the vaccine.192. The CHIKV vaccine of claim 191 , wherein the efficacy of the vaccine is at least 70% claim 191 , relative to unvaccinated subjects claim 191 , following a single dose of the vaccine.193. The CHIKV vaccine of claim 192 , wherein the efficacy of the vaccine is at least 80% claim 192 , relative to unvaccinated subjects claim 192 , following a single dose of the vaccine.194. The CHIKV vaccine of claim 193 , ...

Подробнее

Номер записи: 66

11-01-2018 дата публикации

METHODS AND COMPOSITIONS FOR INDUCTION OF IMMUNE RESPONSE

Номер: US20180008701A1

Автор: Bricker Joseph, Dominowski Paul Joseph, Foss Dennis, Mahan Suman, Mwangi Duncan, Rai Sharath K.

Принадлежит:

The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided. 1. A method of inducing an immune response in a mammal or bird , comprising administering a substantially antigen-free composition comprising a saponin , a sterol , a quaternary amine , and a polyacrylic polymer to the mammal or bird.2. The method of claim 1 , wherein said saponin is a triterpenoid saponin claim 1 , said sterol is cholesterol claim 1 , and said quaternary amine is DDA.3. The method of claim 2 , wherein said triterpenoid saponin is Quil A or a purified fraction thereof.4. The method of claim 1 , wherein the saponin is present in the amount of 1 μg to about 5 claim 1 ,000 μg per dose claim 1 , the sterol is present in the amount of 1 μg to about 5 claim 1 ,000 μg per dose claim 1 , the quaternary amine is present in the amount of 1 μg to about 5 claim 1 ,000 μg per dose claim 1 , and the polyacrylic polymer is present in the amount of 0.0001% volume to volume (v/v) to about 75% v/v.5. The method of claim 1 , wherein the composition consists essentially of the saponin claim 1 , the sterol claim 1 , the quaternary amine claim 1 , and the polyacrylic polymer.6. The method of claim 1 , wherein said composition further comprises a glycolipid.7. The method of claim 6 , wherein the glycolipid is N-(2-Deoxy-2-L-leucylamino-b-D-glucopyranosyl)-N-octadecyldodecanoylamide or a salt thereof.8. The method of claim 6 , wherein said composition does not contain an immunostimulatory oligonucleotide.9. The method of claim 6 , wherein the composition consists essentially of the glycolipid claim 6 , the saponin claim 6 , the sterol claim 6 , the quaternary amine claim 6 , and the polyacrylic polymer.10. The method of claim 6 , wherein the glycolipid is present in the amount of 0. ...

Подробнее

Номер записи: 67

11-01-2018 дата публикации

ADJUVANT COMPOSITION CONTAINING AT LEAST ONE INFLUENZA VIRUS NEUTRALIZING AND BINDING MOLECULE AND VACCINE COMPOSITION CONTAINING SAME

Номер: US20180008702A1

Автор: Ahn Jung Sun, Chang Shin Jae, CHOI Jung Ah, Keum Sun Ju, Kim Pan Kyeom, Lee Soo Young, Lim Byung Pil, Park Eun Bee, Park Sang Tae, SONG Man Ki

Принадлежит: CELLTRION INC.

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses. 1. An adjuvant composition , comprising at least one binding molecule for neutralizing an influenza virus.2. The adjuvant composition of claim 1 , wherein the binding molecule binds to an epitope in a stem region of a hemagglutinin (HA) protein of an influenza A virus.3. The adjuvant composition of claim 1 , wherein an epitope of the binding molecule is at least one selected from the group consisting of i) an epitope comprising any one amino acid residue selected from the group consisting of amino acids at positions 18 claim 1 , 25 claim 1 , 27 claim 1 , 32 claim 1 , 33 claim 1 , 38 claim 1 , 40 claim 1 , 54 claim 1 , 55 claim 1 , 278 claim 1 , 291 claim 1 , 292 claim 1 , 310 claim 1 , 311 claim 1 , 312 and 318 of an HA1 polypeptide; and ii) an epitope comprising any one amino acid residue selected from the group consisting of amino acids at positions 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , 38 claim 1 , 39 claim 1 , 41 claim 1 , 42 claim 1 , 45 claim 1 , 46 claim 1 , 48 claim 1 , 49 claim 1 , 52 claim 1 , 53 claim 1 , 56 claim 1 , 57 claim 1 , 58 claim 1 , 60 and 99 of an HA2 polypeptide.4. The adjuvant composition of claim 1 , wherein the at least one binding molecule is at least one selected from the group consisting of i) a binding molecule claim 1 , comprising a light-chain variable domain including a CDR1 region of SEQ ID NO:1 claim 1 , a CDR2 region of SEQ ID NO:2 and a CDR3 region of SEQ ID NO:3 claim 1 , and a heavy-chain variable domain including a CDR1 region of SEQ ID NO: ...

Подробнее

Номер записи: 68

11-01-2018 дата публикации

CD200 INHIBITORS AND METHODS OF USE THEREOF

Номер: US20180008704A1

Автор: Olin Michael

Принадлежит: Regents of the University of Minnesota

The present invention provides in certain embodiments conjugates comprising at least one CD200 inhibitor and an adjuvant, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a composition comprising a CD200 inhibitor and an adjuvant. 1. A conjugate comprising at least one CD200 inhibitor operably linked to an adjuvant.2. The conjugate of claim 1 , wherein the CD200 inhibitor is a peptide having a length of 5 to 20 amino acids.3. The conjugate of claim 2 , wherein the peptide is 90% identical to amino acid sequence SEQ ID NO:1 claim 2 , SEQ ID NO:2 claim 2 , SEQ ID NO:3 claim 2 , SEQ ID NO:4 claim 2 , SEQ ID NO:5 claim 2 , SEQ ID NO:8 or SEQ ID NO:9.4. The conjugate of claim 1 , wherein the adjuvant is a toll-like receptor (TLR) ligand.5. The conjugate of claim 4 , wherein the adjuvant is a CpG ODN claim 4 , Annexin A2 claim 4 , or Poly ICLC claim 4 , or a fragment thereof.6. The conjugate of claim 5 , wherein the adjuvant is a fragment Annexin A2 claim 5 , and the fragment of Annexin A2 is the first 12-100 amino acid residues of the N-terminus of Annexin A2.7. The conjugate of claim 5 , wherein the adjuvant is a fragment Annexin A2 claim 5 , and the fragment of Annexin A2 is the first 15 amino acid residues of the N-terminus of Annexin A2.8. The conjugate of claim 5 , wherein the adjuvant is MSTVHEILCKLSLEG (SEQ ID NO: 10).9. The conjugate of claim 1 , wherein the adjuvant is linked to the CD200 inhibitor by means of a covalent bond or by means of a linking group.10. A composition comprising the conjugate of and a pharmaceutically acceptable carrier or diluent.11. The composition of claim 10 , further comprising at least one additional CD200 inhibitor.12. The composition of claim 10 , further comprising a cancer vaccine.13. The composition of claim 12 , wherein the cancer vaccine is a tumor lysate ...

Подробнее

Номер записи: 69

27-01-2022 дата публикации

Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response

Номер: US20220023400A1

Автор: Chang Yi Wang

Принадлежит: Ubi Us Holdings LLC

The present invention is directed to novel heterologous promiscuous and artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity of a target antigenic site. The disclosed Th epitopes, when covalently linked to a B cell epitope in a peptide immunogen construct, elicit a strong antibody response to the B cell epitope of the target antigenic site. The Th epitopes are immunosilent on their own, i.e., little, if any, of the antibodies generated by the peptide immunogen constructs will be directed towards the Th epitope, thus allowing a very focused immune response directed to the targeted antigenic site. The heterologous promiscuous Th epitopes provide effective and safe peptide immunogens that do not generate inflammatory, anti-self, cell-mediated immune responses following administration.

Подробнее

Номер записи: 70

08-01-2015 дата публикации

KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250

Номер: US20150010587A1

Автор: Belldegrun Arie, Tso Cho-Lea

Принадлежит: The Regents of the University of California

This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy. 117-. (canceled)18. A nucleic acid encoding a fusion protein comprising a G250 kidney cancer specific antigen attached to a granulocyte macrophage colony stimulating factor (GM-CSF).19. The nucleic acid of claim 18 , wherein said nucleic acid is a deoxyribonucleic acid (DNA).20. The nucleic acid of claim 18 , wherein the G250 antigen is a human G250 antigen and the GM-CSF is a human GM-CSF.21. The nucleic acid of claim 20 , wherein the G250 antigen and the GM-CSF are joined by a peptide linker ranging in length from 2 to about 20 amino acids.22. The nucleic acid of claim 21 , wherein said peptide linker is -Arg-Arg-.23. The nucleic acid of claim 22 , wherein said nucleic acid encodes the polypeptide of SEQ ID NO: 1.24. The nucleic acid of claim 22 , wherein said nucleic acid comprises the nucleic acid of SEQ ID NO: 2.25. The nucleic acid of claim 20 , wherein said nucleic acid is present in an expression cassette.26. The nucleic acid of claim 20 , wherein said nucleic acid is present in a vector.27. (canceled)28. A host cell transfected with a nucleic acid comprising the nucleic acid of .29. The host cell of claim 28 , wherein said host cell is a eukaryotic cell.30. (canceled)31. A method of producing an anti-tumor vaccine claim 18 , said method comprising: culturing a cell transfected with a nucleic acid comprising the nucleic acid of under conditions where said nucleic expresses a G250-GM-CSF fusion protein; and recovering said fusion ...

Подробнее

Номер записи: 71

10-01-2019 дата публикации

ZIKA VIRUS RNA VACCINES

Номер: US20190008946A1

Автор: Ciaramella Giuseppe, Himansu Sunny, Huang Eric Yi-Chun, Zaks Tal

Принадлежит: ModernaTX, Inc.

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease. 1147-. (canceled)148. A method of inducing an immune response in a subject , the method comprising administering to the subject an immunogenic composition comprising a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a Zika virus (ZIKV) prME protein that comprises an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO: 203 , wherein the immunogenic composition is administered in an effective amount to produce an antigen-specific immune response in the subject.149. The method of claim 148 , wherein the antigen specific immune response comprises a T cell response or a B cell response.150. The method of claim 148 , wherein the subject is administered a single dose of the immunogenic composition.151. The method of claim 148 , wherein the subject is administered a booster dose of the immunogenic composition.152. The method of claim 148 , wherein the immunogenic composition is administered to the subject by intradermal injection or intramuscular injection.153. The method of claim 148 , wherein an anti-ZIKV prME antibody titer produced in the subject is increased by at least 1 log and/or at least 2 times relative to a control.154156.-. (canceled)157. The method of claim 153 , wherein the control is selected from an anti-ZIKV prME antibody titer produced in a subject who has not been administered a vaccine against the virus claim 153 , an anti-ZIKV prME antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus claim 153 , an anti-ZIKV prME antibody titer produced in a subject who has been administered a recombinant protein ...

Подробнее

Номер записи: 72

10-01-2019 дата публикации

CHIKUNGUNYA VIRUS RNA VACCINES

Номер: US20190008947A1

Автор: Ciaramella Giuseppe, Elbashir Sayda Mahgoub, Himansu Sunny, Huang Eric Yi-Chun, Zaks Tal

Принадлежит: ModernaTX, Inc.

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease. 1147-. (canceled)148. A method of inducing an immune response in a subject , the method comprising administering to the subject in an amount effective a Chikungunya virus (CHIKV) vaccine comprising a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a CHIKV polyprotein comprising C protein , E1 protein , E2 protein and E3 protein formulated in a lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid , 5-25% non-cationic lipid , 25-55% sterol , and 0.5-15% PEG-modified lipid , in an effective amount to produce an antigen-specific immune response in the subject.149. The method of claim 148 , wherein the antigen specific immune response comprises a T cell response or a B cell response.150. The method of claim 148 , wherein the subject is administered a single dose of the vaccine.151. The method of claim 148 , wherein the subject is administered a booster dose of the vaccine.152. The method of claim 148 , wherein the vaccine is administered to the subject by intradermal injection or intramuscular injection.153. The method of claim 148 , wherein an anti-CHIKV polyprotein antibody titer produced in the subject is increased by at least 1 log and/or at least 2 times relative to a control.154156.-. (canceled)157. The method of claim 153 , wherein the control is selected from an anti-CHIKV polyprotein antibody titer produced in a subject who has not been administered a vaccine against the virus claim 153 , an anti-CHIKV polyprotein antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus claim 153 , an anti-CHIKV polyprotein antibody titer ...

Подробнее

Номер записи: 73

10-01-2019 дата публикации

Novel Adjuvant Compositions

Номер: US20190008953A1

Автор: Bagi Cedo Martin, Childers Tedd Alan, Dominowski Paul Joseph, Jr. Robert John, Krebs Richard Lee, Mannan Ramasamy Mannar, Olsen Mary Kathryn, Thompson James Richard, Weeratna Risini Dhammika, Yancey, Zhang Shucheng

Принадлежит:

This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals. 134-. (canceled)35. An adjuvant composition comprising an immunostimulatory oligonucleotide , a polyacrylic acid polymer and at least two of the following:a. dimethyl dioctadecyl ammonium bromide (DDA);b. a sterol;c. N-(2-deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanamide acetate.36. The adjuvant composition of claim 35 , which comprises DDA and the sterol.37. The adjuvant composition of claim 35 , which comprises DDA and N-(2-deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanamide acetate.38. The adjuvant composition of claim 35 , which comprises the sterol and N-(2-deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanamide acetate.39. The adjuvant composition of claim 35 , which comprises the sterol claim 35 , DDA claim 35 , and N-(2-deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanamide acetate.40. The adjuvant composition of claim 35 , wherein the sterol is cholesterol.41. The adjuvant composition of claim 35 , which is essentially saponin-free.42. A vaccine composition comprising an antigen component and an effective amount of the adjuvant composition of any one of -.43. The vaccine composition according to claim 42 , wherein said vaccine composition is saponin-free. This application is a continuation of U.S. application Ser. No. 15/494,920 filed on Apr. 26, 2017, now allowed, which is a continuation of U.S. application Ser. No. 14/013,299 filed Aug. 29, 2013 now U.S. Pat. No. 9,662,385, which is a division of U.S. application Ser. No. 12/490,767 filed Jun. 24, 2009, now U.S. Pat. No. 8,580,280, which is a non-provisional of U. ...

Подробнее

Номер записи: 74

09-01-2020 дата публикации

DRUG COMBINATIONS

Номер: US20200009247A1

Автор: Azab Mohammad, CORAL Sandra, COVRE Alessia, TAVERNA Pietro

Принадлежит:

The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described. 170-. (canceled)73. The method of claim 72 , wherein Rand Rare independently H claim 72 , OH claim 72 , OMe claim 72 , OEt claim 72 , OCHCHOMe claim 72 , OBn claim 72 , or F.74. The method of claim 72 , wherein X together with the oxygen atoms to which X is bound forms a phosphodiester.75. The method of claim 72 , wherein Rand Rare H.78. The method of claim 77 , wherein the pharmaceutically-acceptable salt is a sodium salt.79. The method of claim 71 , wherein the condition is a myelodysplastic syndrome (MDS).80. The method of claim 71 , wherein the condition is a cancer.81. The method of claim 71 , wherein the condition is a hematological disorder.82. The method of claim 71 , wherein the condition is a disease associated with abnormal hemoglobin synthesis.83. The method of claim 81 , wherein the hematological disorder is a leukemia.84. The method of claim 83 , wherein the leukemia is acute myeloid leukemia (AML).85. The method of claim 83 , wherein the leukemia is acute promyelocyte leukemia.86. The method of claim 83 , wherein the leukemia is acute lymphoblastic leukemia.87. The method of claim 83 , wherein the leukemia is chronic myelogenous leukemia.88. The method of claim 71 , wherein the T-cell activating agent is an anti-CTLA4 antibody.89. The method of claim 71 , wherein the T-cell activating agent is ipilimumab.90. The method of claim 77 , wherein the compound of Formula I or the pharmaceutically-acceptable salt thereof is administered before administration of the T-cell activating agent. This ...

Подробнее

Номер записи: 75

10-01-2019 дата публикации

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

Номер: US20190010190A1

Автор: HILF Norbert, SCHOOR Oliver, SINGH Harpreet, TRAUTWEIN Claudia, WALTER Steffen, WEINSCHENK Toni

Принадлежит:

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. 1. A method of treating a patient who has cancer , comprising administering to the patient an effective amount of an antibody specifically binding to an MHC class I or II molecule complexed with a HLA-restricted antigen consisting of the amino acid sequence of KIQEILTQV (SEO ID NO: 14) , wherein the cancer is selected from the group consisting of glioblastoma , renal cell carcinoma , melanoma , endometrial cancer , esophageal squamous cell carcinoma , pancreatic cancer , and urothelial cancer.2. The method of claim 1 , wherein the antibody is a polyclonal antibody claim 1 , a monoclonal antibody claim 1 , or a chimeric antibody.3. The method of claim 1 , wherein the antibody binds to the HLA-restricted antigen with a binding affinity of below 20 nanomolar.4. The method of claim 1 , wherein the antibody binds to the MHC class I molecule complexed with the HLA-restricted antigen.5. The method of claim 1 , wherein the antibody is humanized.6. The method of claim 1 , wherein the effective amount of the antibody is from about 1 μg/kg to about 100 mg/kg of body weight per day.7. The method of claim 1 , wherein the antibody is conjugated with a toxin.8pseudomonas. The method of claim 7 , wherein the toxin is selected from the group consisting of diptheria toxin claim 7 , exotoxin A claim 7 , ...

Подробнее

Номер записи: 76

03-02-2022 дата публикации

Personalised immunogenic peptide identification platform

Номер: US20220031823A1

Автор: Eniko R. TOKE, Eszter Somogyi, József Toth, Julianna Lisziewicz, Katalin Pántya, Levente Molnár, Mónika Megyesi, Orsolya Lorincz, Zsolt Csiszovszki

Принадлежит: Treos Bio Ltd

The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing personalised pharmaceutical compositions comprising such polypeptide fragments, human subject-specific pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of the subject.

Подробнее

Номер записи: 77

03-02-2022 дата публикации

MUCOSAL ADJUVANT

Номер: US20220031838A1

Автор: GOTANDA Takuma, Kishimoto Naoki, MISUMI Shogo, MITSUMATA Ryotaro, NAKATA Nagisa

Принадлежит:

A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen. 1. A mucosal adjuvant , comprising:TGDK.2. A mucosal adjuvant composition , comprising:TGDK; anda pharmaceutically acceptable carrier.3. A mucosal vaccine composition , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the mucosal adjuvant of ; and'}an immunogen.4. The composition of claim 3 , wherein the immunogen is a whole particle or a split antigen of influenza virus.5. A method for preparing the mucosal vaccine composition of claim 3 , the method comprising:mixing TGDK with an immunogen.6. TGDK adapted for use as a mucosal adjuvant.7. A composition claim 3 , comprising:TGDK; andan immunogen,wherein the composition is suitable for use in mucosal vaccine therapy.89-. (canceled)10. A mucosal vaccine therapy claim 3 , comprising:administering an effective amount of a composition comprising TGDK and an immunogen to a subject in need thereof. The present invention relates to a mucosal adjuvant which enhances the mucosal immunity induction of an antigen.Mucosal vaccines initiate both mucosal local immunity and systemic immune response by the transmucosal (e.g., transnasal) administration of antigens, and can thereby construct double defense lines against pathogens. On the other hand, mucosal vaccines practically used are live vaccines having infectiveness or vaccines based on mucosotropic special toxins as antigens. Other inactivated antigens cannot induce sufficient immunity by single administration and need to be combined with adjuvants or the like.Heretofore, attenuated pathogens having infectiveness have been used as methods for initiating sufficient immunity with mucosal vaccines. However, attenuated live vaccines cause strong side ...

Подробнее

Номер записи: 78

19-01-2017 дата публикации

COMBINATION OF VACCINATION AND OX40 AGONISTS

Номер: US20170014496A1

Автор: Fotin-Mleczek Mariola, Kallen Karl-Josef, SCHMOLLINGER Jan C.

Принадлежит:

The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist. 1. A vaccine/agonist combination comprising:(i) as vaccine an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and(ii) as agonist a composition comprising an OX40 agonist.2. The combination according to claim 1 , wherein the OX40 agonist is a binding molecule which specifically binds to OX40.3. The combination according to or claim 1 , wherein the binding molecule is selected from the group consisting of an agonistic antibody or a nucleic-acid encoded agonistic antibody claim 1 , an aptamer claim 1 , a protein comprising an OX40 ligand or a nucleic-acid encoded OX40 ligand claim 1 , and a small molecule agonist.4. The combination according to claim 3 , wherein the agonistic antibody or an antigen binding fragment thereof claim 3 , or a nucleic-acid encoded agonistic antibody or an antigen binding fragment thereof claim 3 , is directed against OX40.5. The combination according to claim 4 , wherein the agonistic antibody directed against OX40 is monoclonal antibody 9B12.6. The combination according to claim 3 , wherein the protein comprising an OX40 ligand or a nucleic-acid encoded OX40 ...

Подробнее

Номер записи: 79

19-01-2017 дата публикации

Prostate cancer vaccine

Номер: US20170014498A1

Автор: Brian M. Olson, Douglas G. Mcneel

Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.

Подробнее

Номер записи: 80

19-01-2017 дата публикации

Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof

Номер: US20170014506A1

Автор: Gu Ying, LI Shaowei, Luo Wenxin, Song Cuiling, Xia Ningshao, Yang Chunyan

Принадлежит:

Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid. 1. A method for enhancing immunogenicity of a target protein , comprising obtaining a fusion protein comprising CRM197 or a fragment thereof and the target protein , wherein said CRM197 or a fragment thereof enhances immunogenicity of the target protein.2. The method of claim 1 , wherein the fragment of CRM197 comprises Fragment A claim 1 , Transmembrane Domain T claim 1 , and/or Receptor Binding domain R of CRM197.3. The method of claim 2 , wherein the fragment of CRM197 comprises Fragment A claim 2 , or Fragment A and Transmembrane Domain T.4. The method of claim 2 , wherein the fragment of CRM197 comprises aa 1-190 of CRM197 claim 2 , or comprises aa 1-389 of CRM197.5. The method of claim 1 , wherein CRM197 has an amino acid sequence as set forth in SEQ ID NO: 2.6. The method of claim 1 , wherein the fusion protein is obtained by fusion expression of CRM197 or the fragment of CRM197 with the target protein claim 1 , optionally using a linker.7. The method of claim 1 , wherein the fusion protein comprises CRM197 or the fragment of CRM197 which is linked to the N- ...

Подробнее

Номер записи: 81

19-01-2017 дата публикации

ANTI-TUMOR COMPOSITIONS AND USES THEREOF

Номер: US20170014507A1

Автор: BAZMORELLI Adriana, Maraskovsky Eugene

Принадлежит:

The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a TLR ligand and a Flt3 ligand. 1. A composition , the composition comprising at least one tumor antigen , a saponin-based adjuvant , a TLR ligand and a Flt3 ligand.2. The composition as claimed in in which the saponin-based adjuvant is ISCOMATRIX™ adjuvant.3. The composition as claimed in in which the Flt3 ligand is a chimera of human Flt3 ligand and human Fc.4. The composition as claimed in in which the TLR ligand is a TLR 3 ligand.5. The composition as claimed in which the TLR 3 ligand is Poly IC.6. The composition as claimed in in which the TLR ligand is a TLR 4 ligand.7. The composition as claimed in which the TLR 4 ligand is monophosphoryl lipid A (MPL).8. The composition as claimed in in which the TLR ligand is a TLR 5 ligand.9. The composition as claimed in which the TLR 5 ligand is Flagellin.10. The composition as claimed in in which the TLR ligand is a TLR 7/8 ligand.11. The composition as claimed in which the TLR 7/8 ligand is imidazoquinoline (R848).12. The composition as claimed in in which the TLR ligand is a TLR 9 ligand.13. The composition as claimed in which the TLR 9 ligand is CpG.14. A method of treating a tumor in a subject the method comprising administering to the subject a composition as claimed in .15. A method of protecting a subject against development of a tumor claim 1 , the method comprising administering to the subject a composition as claimed in prior to development of the tumor.16. A method of inducing an immune response against a tumor in a subject claim 1 , the method comprising administering to the subject a composition as claimed in . This application is a continuation of U.S. patent application Ser. No. 14/447,532, filed Jul. 30, 2014, which application claims convention priority from Australian Patent application No. 2013902846, filed Jul. 31, 2013, the ...

Подробнее

Номер записи: 82

18-01-2018 дата публикации

COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE

Номер: US20180015101A1

Автор: ANEGON Ignacio, Blancou Philippe, POGU Julien, SIMON Thomas

Принадлежит:

The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase-1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance. 1. A method for inducing immune tolerance in a patient suffering from or at risk of a condition related to immune tolerance , comprisingadministering to the patient a therapeutically effective amount of a composition comprising (i) a Heme Oxygenase-1 (HO-1) inducer and (ii) at least one pathogenic antigen involved in the condition,wherein the composition is administrated topically or intradermally to a patient's skin of the patient.2. The method of claim 1 , wherein the pathogenic antigen is not insulin.3. The method of wherein the HO-1 inducer is not rapamycin.4. The method according to claim 2 , wherein the HO-1 inducer is Cobalt protoporphyrin (CoPP) claim 2 , protoporphyrin IX containing a ferric iron ion (Heme B) with a chloride ligand (Hemin) claim 2 , hematin claim 2 , iron protoporphyrin or heme degradation products.5. The method according to claim 2 , wherein said pathogenic antigen is an autoantigen claim 2 , an alloantigen or an allergen.6. The method according to claim 5 , wherein said autoantigen is selected from the group consisting of myelin-related antigen claim 5 , myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP).7. The method according to claim 5 , wherein said autoantigen is selected from the group consisting of glutamic acid decarboxylase 65 (GAD65) claim 5 , glial fibrillary acidic protein (GFAP) claim 5 , islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) claim 5 , insulinoma-associated antigen-2 (IA-2) and zinc transporter 8 (ZnT8).8. The method according to claim 5 , wherein said autoantigen is type II collagen (CTII).9. The method according to claim 5 ...

Подробнее

Номер записи: 83

15-01-2015 дата публикации

CHOLERA TOXIN CHIMERA AND ITS USE AS A STAPH VACCINE

Номер: US20150017199A1

Автор: Tinker Juliette

Принадлежит:

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from and an antigenic material from a -specific polypeptide. 1S. aureus. An specific polypeptide antigen comprising a truncated iron-regulated surface determinant A (IsdA).2S. aureus. The specific polypeptide antigen of having a sequence of SEQ ID NO:4 or a protein with 90% homology thereto.3. The protein of claim 1 , wherein said (IsdA) protein comprises the amino acid sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6.4. A chimeric protein comprising the antigen of and an adjuvant protein.5. The chimeric protein of comprising SEQ ID NO:4 or a protein with 90% homology thereto.6. The chimeric protein of wherein said adjuvant is selected form the group consisting of: a portion of cholera toxin claim 5 , a portion of heat labile toxin claim 5 , or a portion of shiga toxin.7. The chimeric protein of wherein said adjuvant is cholera toxin subunit A or B claim 6 , heat labile toxin subunit B claim 6 , or Shiga toxin subunit B.8. The chimeric protein of wherein said adjuvant is cholera toxin adjuvant protein is CTAor CTB.9. The chimeric protein of wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.10. The chimeric protein of wherein the chimeric protein is a fusion protein.11. The chimeric protein of comprising a sequence of SEQ ID NO: 2 claim 8 , 3 claim 8 , 5 claim 8 , or 6 claim 8 , or a sequence with 90% homology thereto.12. An immunogenic composition comprising the chimeric protein of and a carrier.13. The immunogenic ...

Подробнее

Номер записи: 84

15-01-2015 дата публикации

SYNTHETIC TOLL-LIKE RECEPTOR-4 (TLR-4) AGONIST PEPTIDES

Номер: US20150017202A1

Автор: Geliebter Jan, Mittelman Abraham, Suriano Robert, TIWARI Raj

Принадлежит: AV Theapeutics, Inc.

The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both. 1. A method of identifying an immunological adjuvant , which comprises isolating a compound that specifically binds to an anti-lipopolysaccharide (LPS) antibody or antigen binding fragment thereof , and activates NF-κB in a cell , wherein activation of NF-κB identifies the peptide as an immunological adjuvant.2. The method of claim 1 , wherein the anti-lipopolysaccharide antibody binds to LPS core.3. The method of claim 1 , wherein the anti-lipopolysaccharide antibody binds to lipid A.4. The method of claim 1 , wherein the anti-lipopolysaccharide antibody is 2D7/1.5. The method of claim 1 , wherein activation of NF-κB is indicated by nuclear localization of NF-κB in a cell.6. The method of claim 1 , wherein activation of NF-κB is indicated by secretion of one or more inflammatory cytokines from an antigen presenting cell.7. The method of claim 6 , wherein the antigen presenting cell is a macrophage.8. The method of claim 1 , wherein the compound is identified by screening a phage display library.9. The method of claim 1 , wherein the compound is a peptide.10. The method of claim 9 , wherein the peptide is from 4 to 10 amino acids in length.11. The method of claim 9 , wherein the peptide is from 7 to 15 amino acids in length.12. A method of inducing an immune response in a subject claim 9 , which comprises administering an immunogen and an adjuvant peptide to a subject in an amount effective to produce an immune response therein claim 9 , wherein said adjuvant peptide is administered in ...

Подробнее

Номер записи: 85

18-01-2018 дата публикации

In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles

Номер: US20180015160A1

Автор: Franziska Lechner, Martin F. Bachmann, Tazio Storni

Принадлежит: KUROS BIOSCIENCES AG

The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.

Подробнее

Номер записи: 86

21-01-2016 дата публикации

DRUG COMBINATIONS

Номер: US20160015805A1

Автор: Azab Mohammad, CORAL Sandra, COVRE Alessia, TAVERNA Pietro

Принадлежит:

The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described. 1. A combination comprising a compound of Formula I or a pharmaceutically-acceptable salt thereof:{'br': None, '(5-azacytosine group)-L-(guanine group)\u2003\u2003(I)'}wherein L is a phosphorous-containing linker wherein the number of phosphorus atoms in L is 1; and (a) a T-cell activating agent;', '(b) a cancer vaccine;', '(c) an IDO inhibitor; and', '(c) an adjuvant., 'one or more ancillary therapeutic component(s) selected from3. The combination of or , wherein Rand Rare independently H , OH , OMe , OEt , OCHCHOMe , OBn , or F.4. The combination of any one of the preceding claims wherein X together with the oxygen atoms to which X is bound forms a phosphodiester.5. The combination of any one of the preceding claims wherein Rand Rare H.6. The combination of any one of the preceding claims , wherein the compound of Formula I is any one of I-(1-44).9. The combination of wherein said salt is a sodium salt.10. The combination of any one of the preceding claims wherein the compound of Formula I or salt thereof is in the form of a formulation claim 8 , being dissolved in a substantially anhydrous solvent comprising about 45% to about 85% propylene glycol; about 5% to about 45% glycerin; and 0% to about 30% ethanol.11. The combination of wherein said solvent comprises about 65% to about 70% propylene glycol; about 25% to about 30% glycerin claim 10 , and 0% to about 10% ethanol.12. The combination of wherein said solvent comprises 65% to 70% propylene glycol and 25% to 30% glycerin claim 11 , any balance being ...

Подробнее

Номер записи: 87

19-01-2017 дата публикации

Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof

Номер: US20170015713A1

Автор: Chunyan Yang, Cuiling SONG, Ningshao Xia, Shaowei Li, Wenxin Luo, Ying Gu

Принадлежит: Xiamen Innovax Biotech Co Ltd, XIAMEN UNIVERSITY

Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

Подробнее

Номер записи: 88

17-01-2019 дата публикации

METHODS AND MATERIALS FOR TREATING CANCER

Номер: US20190015489A1

Автор: Kottke Timothy J., Melcher Alan A., Pulido Jose S., Selby Peter, Vile Richard G.

Принадлежит:

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided. 1. A method for treating cancer present in a mammal, wherein said method comprises administering, to said mammal, a nucleic acid library under conditions wherein nucleic acid members of said nucleic acid library are expressed in said mammal, thereby reducing the number of viable cancer cells present within said mammal. This application is a divisional application of U.S. Ser. No. 13/578,224, filed Aug. 9, 2012, which is a National Stage application under 35 U.S.C. § 371 and claims benefit of International Application No. PCT/US2011/024397, having an International Filing Date of Feb. 10, 2011, which claims the benefit of U.S. Provisional Application Ser. No. 61/303,222, filed Feb. 10, 2010. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.This document relates to methods and materials involved in treating cancer. For example, this document provides methods and material for using nucleic acid libraries to treat cancer.Cancer is a serious illness that affects many people every year. In general, there are several common methods for treating cancer: surgery, chemotherapy, radiation therapy, immunotherapy, and biologic therapy. When initially diagnosed with cancer, a cancer specialist such as an oncologist can provide a patient with various cancer treatment options. Typically, an oncologist will recommend the best treatment plan based on the type of cancer, how far it has spread, and other important factors like the age and general health of the patient.This document provides methods and materials related to treating cancer. For example, this document provides methods and materials for using nucleic acid libraries to treat cancer. As described herein, a nucleic acid library can be used to deliver a large number of ...

Подробнее

Номер записи: 89

16-01-2020 дата публикации

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPROGRAMING IMMUNE ENVIRONMENT IN A SUBJECT IN NEED THEREOF

Номер: US20200016177A1

Автор: de Medina Philippe, LEIGNADIER Julie, Poirot Marc, RECORD Michel, SILVENTE POIROT Sandrine

Принадлежит:

The present invention relates to methods and pharmaceutical compositions for reprogramming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes. 1. A method of promoting Th1 differentiation and functionality in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Dendrogenin A (DDA).2. A method of inhibiting Treg differentiation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA.3. A method of promoting maturation of dendritic cells in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA.4. A method of enhancing the proliferation , migration , persistence and/or cytoxic activity of CD8+ T cells in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA.5. A method of treating cancer in a subject in need thereof comprising i) quantifying the density of CD8+ T cells in a tumor tissue sample obtained from the subject ii) comparing the density quantified at step i) with a predetermined reference value and iii) administering to the subject a therapeutically effective amount of DDA when the density quantified at step i) is lower than the predetermined reference value.6. A vaccine composition comprising an immunoadjuvant together with one or more antigens , for inducing an immune response against said one or more antigens wherein the ...

Подробнее

Номер записи: 90

21-01-2021 дата публикации

Topical hyper-allergenic composition and method of treating using the same

Номер: US20210015912A1

Автор: Michael J. Dochniak

Принадлежит: Individual

A topical hyper-allergenic composition that includes a first protein that exhibits amyloid-β structure and immunogenicity in humans, a second protein that exhibits immunogenicity in humans, an immunologic adjuvant, and a carrier.

Подробнее

Номер записи: 91

21-01-2021 дата публикации

VACCINE DELIVERY METHOD

Номер: US20210015916A1

Автор: HARN DONALD A., QUEIROZ RAFAELLA, Samli Emily-Joy Farah, Shollenberger Lisa

Принадлежит:

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions. 1. (canceled)2. A vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2) , an influenza antigen , and a TLR9 agonist.3. A vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2) , a hepatitis antigen , and a TLR9 agonist.4. The vaccine composition of claim 2 , wherein the TLR9 agonist comprises a CpG oligodeoxynucleotide (ODN).5. The vaccine composition of claim 2 , wherein the influenza antigen comprises an influenza A claim 2 , influenza B claim 2 , or influenza C antigen.6. The vaccine composition of claim 2 , wherein the influenza antigen comprises a recombinant nucleoprotein (rNP) influenza virus antigen.7. The vaccine composition of claim 2 , wherein the influenza antigen comprises a whole-inactivated influenza virus.8. The vaccine composition of claim 3 , wherein the hepatitis antigen comprises a hepatitis A claim 3 , hepatitis B claim 3 , or hepatitis C antigen.9. The vaccine composition of claim 3 , wherein the hepatitis antigen comprises a recombinant Hepatitis B antigen (rHepBag).10. The vaccine composition of claim 2 , wherein the vaccine composition is lyopholized.11. A method of producing an immune response in a subject claim 2 , the method comprising administering a vaccine composition of to the subject.12. A method of producing an immune response in a subject claim 3 , the method comprising administering a vaccine composition of to the subject.13. A method of vaccinating a subject to influenza claim 2 , the method comprising ...

Подробнее

Номер записи: 92

16-01-2020 дата публикации

Compositions and Methods of Identifying Tumor Specific Neoantigens

Номер: US20200016251A1

Автор: Hacohen Nir, Wu Catherine J.

Принадлежит:

The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses. 120.-. (canceled)21. A method for selecting a subject-specific plurality of epitopes for preparing a cancer cell specific pharmaceutical composition to treat cancer in a single subject , the method comprising '(ii) whole genome sequencing or whole exome sequencing non-cancer cell nucleic acids from a second biological sample comprising non-cancer cells from the single subject, thereby obtaining a second plurality of nucleic acid sequences comprising non-cancer cell nucleic acid sequences;', '(a) (i) whole genome sequencing or whole exome sequencing cancer cell nucleic acids from a first biological sample comprising cancer cells from the single subject, thereby obtaining a first plurality of nucleic acid sequences comprising cancer cell nucleic acid sequences; and'} wherein the identified plurality of cancer specific nucleic acid sequences encodes two or more different MHC-binding epitope sequences of two or more different proteins that are expressed by the cancer cells, and', 'wherein each of the two or more different MHC-binding epitope sequences of the two or more different proteins comprises a cancer specific amino acid mutation that is not present in the non-cancer cells from the single subject;, '(b) identifying a plurality of cancer specific nucleic acid sequences that are specific to the cancer cells of the single subject based on a comparison of the first plurality of nucleic acid sequences obtained in (a)(i), to the second plurality of nucleic acid sequences obtained in (a)(ii),'}{'sub': '50', '(c) selecting at least two high affinity MHC-binding epitope sequences based ...

Подробнее

Номер записи: 93

17-01-2019 дата публикации

Methods for Inducing Migration by Dendritic Cells and An Immune Response

Номер: US20190017024A1

Автор: Geoffrey William Stone

Принадлежит: UNIVERSITY OF MIAMI

Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE 2 .

Подробнее

Номер записи: 94

28-01-2016 дата публикации

COMPOSITION FOR BUFFERED AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND ITS USE FOR ENHANCING AN IMMUNE RESPONSE

Номер: US20160022719A1

Автор: BURKHART David, DUTTA Nupur, Johnson David

Принадлежит:

There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator. 1. A composition comprising (i) an aminoalkyl glucosaminide phosphate or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a HEPES buffer sufficient to provide a pharmaceutically acceptable pH range.2. The composition of wherein said buffer is selected from the group consisting of HEPES having a pH that is within a pharmaceutically acceptable pH range.3. The composition according to wherein said buffer is HEPES having a pH between about 7 and about 8.4. The composition according to having a pH of about 7.0.5. The composition according to having a pH=7.0.7. The composition of wherein n is an integer from 0 to 2 inclusive.8. The composition of wherein R claim 6 , R claim 6 , and Reach independently contain from about 7 to about 16 carbon atoms.9. The composition of wherein R claim 6 , R claim 6 , and Reach independently contain from about 9 to about 14 carbon atoms.10. The composition of wherein n is 0.11. The composition of wherein Ris CO2H.12. The composition of wherein Ris POH.13. The composition of wherein Ris H.17. The composition of wherein Ris a phosphate group and the counterion is selected from the group consisting of monoethanolamine claim 6 , diethanolamine and triethanolamine.18. The composition of wherein the counterion is the monoethanolamine.19. The composition of wherein the counterion is the monoethanolamine.20. The composition of in the form of a dispersion.21. The composition of in the form of a solution.22. The composition of or in the form of a clear solution.23. The composition of in which the mixture claim 22 , solution claim 22 , and clear solution is nanoparticulate composition having a particle size of ≦200 mμ.24. The composition of wherein said solution is used as an immunomodulator.25. The composition of wherein said composition has a sterile ...

Подробнее

Номер записи: 95

28-01-2016 дата публикации

Method for Treating Cancers by Alternating Immunotherapeutics and Directly Oncolytic Therapeutics

Номер: US20160022810A1

Автор: Cohen David I.

Принадлежит:

The present invention describes a unique immunotherapeutic method of treating cancer with the administration of CATS™ or an alternation of CATS™ immunotherapeutic followed by a directly oncolytic compound or agent, which protocol (BYES) can be by example an agent specifically targeting cancer stern cells, other cancer-specific growth pathways, radiotherapy, or compartmentalized chemotherapy. The BYES combination of CATS™ immunotherapeutic with cyclophosphamide delivers a very high statistical significant difference in survival and primary tumor control compared against either agent individually. 1. A method for treating cancer in a patient comprising:a. administering a therapeutically effective amount of a Cysteine-rich Adjuvant;b. causing a cessation of growth or regression of said cancer in said patient.2. The method of wherein said administering is initiated with a bolus dosing to arrest tumor progression.3. The method of wherein the metabolic breakdown of the Cysteine-rich Adjuvant is delayed by genetic modifications or other means claim 1 , producing a sustained action.4. The method of wherein said cancer is endstage.5. A method for treating cancer in a patient comprising:a. Administering a therapeutically effective dose of an immunotherapeutic thereby activating and priming the immune system to be on alert to fight the cancer;b. Administering a second therapeutically effective dose of an oncolytic agent to kill the cancer cells causing them to shed cancer antigens;c. Causing a cessation of growth or regression or cure of said cancer in said patient.6. The method of where the immunotherapeutic is a Cysteine-rich Adjuvant claim 5 , and the oncolytic agent is cyclophosphamide claim 5 , the oncolytic having an additional activity to antagonize TReg immune suppression.7. The method of where said cancer is at an advanced stage and/or extensively metastatic.8. The method of (b) where the oncolytic agent induces the cancer cell to undergo apoptosis.9. The method of ...

Подробнее

Номер записи: 96

26-01-2017 дата публикации

VACCINE COMPOSITIONS

Номер: US20170021008A1

Автор: Drew Jeffrey

Принадлежит:

The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: Rrepresents Calkyl; Rrepresents hydrogen or Calkyl; and Rrepresents Calkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient. 2. The method according to claim 1 , in which the compound of formula (I) is dimethylglycine or trimethylglycine.3. The method according to claim 2 , in which the compound of formula (I) is dimethylglycine.4. The method according to claim 1 , in which the aqueous composition further comprises one or more sugars.5. The method according to claim 4 , in which the one or more sugars are sucrose and raffinose.6. The method according to claim 1 , in which the aqueous composition further comprises an adjuvant.7. The method according to claim 6 , in which the adjuvant is an aluminium salt adjuvant8. The method according to claim 1 , in which the immunogenicity of the influenza antigen is increased during the (a) freezing claim 1 , (b) heat-treating claim 1 , and/or (c) freeze-drying of the aqueous composition.9. (canceled)1113-. (canceled)15. The method according to claim 14 , wherein the patient is (a) a child claim 14 , an elderly patient and/or a patient suffering from lung diseases claim 14 , diabetes claim 14 , cancer claim 14 , or kidney or heart problems claim 14 , or (b) a patient who has previously suffered an adverse-reaction to an influenza vaccine. The invention relates the use of specific dialkylglycine and trialkylglycine excipients to increase the immunogenicity of influenza antigens, as well as to methods for increasing the immunogenicity of influenza antigens, to vaccine compositions obtainable using the method, and to the use of the vaccine compositions in vaccination of patients.Influenza virus is a member of the ...

Подробнее

Номер записи: 97

26-01-2017 дата публикации

NOVEL IMMUNOADJUVANT FLAGELLIN-BASED COMPOUNDS AND USE THEREOF

Номер: US20170021015A1

Автор: Sirard Jean-Claude

Принадлежит:

The present invention relates to novel peptide compounds derived from flagellin originating from that exhibit an in vivo immune adjuvant activity. 1. An immunoadjuvant compound comprising:a) a N-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting from the amino acid residue located at position 1 of SEQ ID NO 1 and ending at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 99 to 173 of SEQ ID NO 1; andb) a C-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID NO 1 and ending at the amino acid residue located at position 494 of SEQ ID NO. 1, 'the said N-terminal peptide is directly linked to the said C-terminal peptide.', 'wherein2. The immunoadjuvant compound according to claim 1 , wherein the said N-terminal peptide is selected from the group consisting of the amino acid sequences 1-99 claim 1 , 1-137 claim 1 , 1-160 and 1-173 of SEQ ID NO 13. The immunoadjuvant compound according to claim 1 , wherein the said C-terminal peptide is selected from the group consisting of the amino acid sequences 401-494 and 406-494 of SEQ ID NO 14. The immunoadjuvant compound of claim 1 , wherein the said N-terminal and C-terminal peptides consist of the amino acid sequences 1-173 and 401-494 of SEQ ID NO 1 claim 1 , respectively5. The immunoadjuvant compound of claim 1 , wherein the said N-terminal and C-terminal peptides consist of the amino acid sequences 1-160 and 406-494 of SEQ ID NO 1 claim 1 , respectively.6. The immunoadjuvant compound of claim 1 , wherein the said N-terminal and C-terminal peptides consist of the amino acid sequences 1-137 and 406-494 of SEQ ID NO 1 claim 1 , respectively.7. The immunoadjuvant compound of claim 1 , wherein the said N-terminal peptide and the said C- ...

Подробнее

Номер записи: 98

22-01-2015 дата публикации

GRANULYSIN IN IMMUNOTHERAPY

Номер: US20150023910A1

Автор: Clayberger Carol, Krensky Alan M.

Принадлежит:

Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors. 1. A method of enhancing an immune response against a target antigen , comprising administering to a subject in need thereof:(a) a therapeutically effective amount of the target antigen and a monocyte-derived dendritic cell produced by contacting a monocyte with an effective amount of 15 kD granulysin; or,(b) co-administering the target antigen and the 15 kD granulysin to the subject.2. The method of claim 1 , further comprising contacting the monocyte with an additional agent other than 15 kD granulysin that enhances dendritic cell maturation.3. The method of claim 2 , wherein the additional agent that enhances dendritic cell maturation comprises GM-CSF claim 2 , M-CSF claim 2 , IL-4 claim 2 , IL-6 claim 2 , IL-7 claim 2 , IL-13 claim 2 , flt-3L claim 2 , TNF-α claim 2 , IFN-α claim 2 , CpG motif containing oligonucleotides claim 2 , toll-like receptors claim 2 , heparan sulfate claim 2 , calcium ionophore claim 2 , or a combination thereof.4. The method of claim 1 , wherein the target antigen comprises a protein claim 1 , a polypeptide claim 1 , a polysaccharide claim 1 , a lipid claim 1 , a DNA molecule claim 1 , a RNA molecule claim 1 , a whole cell lysate claim 1 , an apoptotic cell claim 1 , a live claim 1 , attenuated claim 1 , or heat-killed antigen claim 1 , or a ...

Подробнее

Номер записи: 99

10-02-2022 дата публикации

Rabies Composition Comprising Pika Adjuvant

Номер: US20220040289A1

Автор: Fang Liu, Lietao Li, Yi Zhang

Принадлежит: Yisheng Biopharma Singapore Pte Ltd

The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody.

Подробнее

Номер записи: 100